Genistein treatment improves fracture resistance in obese diabetic mice

BMC Endocrine Disorders

Table 1 Histomorphometry of the femur two-way analysis of variance

	Lean STD	Lean + GEN	Obese STD	Obese + GEN	Genotype effect (P)	Treatment effect (P)	Genotype * treatment interaction (P)
Starting body mass (g)	22.1 ± 0.92	21.7 ± 0.53	37.0 ± 1.86	36.54 ± 1.11	0.01	0.73	0.99
Final body mass (g)	24.8 ± 0.92	23.4 ± 0.46	50.7 ± 2.28	43.7 ± 1.29	0.01	0.01	0.06
PE Bone area (B.Ar.; mm²)	0.79 ± 0.15	0.50 ± 0.07	0.85 ± 0.06	0.84 ± 0.04	0.04	0.11	0.12
PE Total area (Tt.Ar.; mm²)	1.46 ± 0.26	0.84 ± 0.13	1.64 ± 0.17	1.44 ± 0.09	0.04	0.03	0.25
MS Cortical area (Ct.Ar.; mm²)	1.15 ± 0.06	1.20 ± 0.06	1.17 ± 0.03	1.08 ± 0.07	0.36	0.70	0.22
MS IMAX (mm⁴)	2.17 ± 0.20	2.11 ± 0.25	2.06 ± 0.12	1.98 ± 0.27	0.59	0.75	0.95
MS IMIN (mm⁴)	1.07 ± 0.12	1.29 ± 0.07	1.25 ± 0.06	1.09 ± 0.13	0.91	0.77	0. 09
MS J (mm⁴)	3.24 ± 0.31	3.40 ± 0.31	3.31 ± 0.17	3.07 ± 0.40	0.67	0.90	0.53

Data displayed as mean ± SE
STD fed standard chow; GEN fed 600 genistein/kg
PE proximal epiphysis of the femur; MS midshaft of the femur
IMAX maximum second moment of area; IMIN minimum second moment of area; J polar moment of area

ISSN: 1472-6823